Hologic to Showcase Award Winning 3D Mammography and Other Advanced
Imaging Technologies at RSNA 2012
BEDFORD, Mass., Nov. 19, 2012 /PRNewswire/ -- Hologic, Inc.
(Hologic or the Company) (Nasdaq: HOLX), a leading developer,
manufacturer and supplier of premium diagnostics products, medical
imaging systems and surgical products dedicated to serving the
healthcare needs of women, will feature its newest women's health
products at the 98th Scientific Assembly and Annual Meeting of the
Radiological Society of North
America (RSNA) at McCormick Place in Chicago, November 25
through November 29.
"The RSNA annual conference is always an exciting time for
Hologic, but this year we are particularly pleased to be able to
highlight our considerable advances in 3D mammography," stated
Rob Cascella, President and CEO of
Hologic. "Since U.S. approval last year, we've seen a great deal of
interest in this breakthrough technology, with many early users
becoming instant believers of and advocates for our 3D mammography
platform. Hardly a day goes by without another TV or newspaper
story on how the technology finds cancers missed with traditional
mammography. In addition, we are beginning to see more
peer-reviewed papers accepted for publication in major scientific
journals and are confident these papers will confirm the extremely
compelling benefits of 3D mammography – improved accuracy compared
to conventional mammography, resulting in earlier detection of
cancers and a reduced need for recalls."
The RSNA is an international society of radiologists, medical
physicists and other medical professionals with more than 50,000
members across the globe. RSNA hosts the largest medical meeting in
the U.S., drawing 60,000 attendees annually. The theme for RSNA's
98th Scientific Assembly and Annual Meeting is "People
First."
3D Mammography Highlights at RSNA
Prominently featured at RSNA this year is Hologic's Selenia
Dimensions 3D mammography (breast tomosynthesis) system. The
technology was approved by the U.S. Food and Drug Administration
(FDA) in February 2011 and has been
available in countries recognizing the CE mark since 2008.
Hologic's 3D mammography technology is available in 47 states in
the United States and 28 other countries.
Hologic's 3D mammography system placed first in the digital
mammography category in the KLAS 2012 annual survey of healthcare
executives and clinicians. KLAS is a research firm specializing in
monitoring and reporting on the performance of healthcare vendors.
3D mammography was recently selected by AuntMinnie as the "hottest
clinical procedure" of the year for the third consecutive year.
AuntMinnie is the largest and most comprehensive Web site for
medical imaging professionals worldwide. In October, the Cleveland
Clinic picked 3D mammography as one of the Top 10 Medical
Innovations for 2013 at the Clinic's 10th annual Medical Innovation
Summit.
Fifteen of the clinical papers and over 50 of the workshops,
seminars, poster sessions and scientific papers to be presented at
the conference are on 3D mammography. Clinical presentations
cover the use of tomosynthesis in screening and diagnostic
applications.
Hologic is once again offering training sessions including
hands-on experience reading 3D breast tomosynthesis images in
combination with conventional and synthesized 2D images. Brief
lectures will provide an overview of the technologies prior to the
hands-on sessions. Each program will be taught by a leading breast
imaging radiologist. Radiologists can register for a workshop
through the RSNA meeting web site.
Some of Hologic's other advances in breast tomosynthesis on
display at the conference include its tomosynthesis biopsy option
for use with the Affirm biopsy guidance system and its C-View
synthesized 2D image option. The tomosynthesis biopsy option is CE
marked and is pending FDA clearance. C-View images are designed to
be used with tomosynthesis in the screening and diagnosis of breast
cancer, eliminating the need for a separate 2D exposure. The C-View
synthesized 2D image option received CE marking in 2011 and while
not yet approved in the U.S., received a favorable vote from an FDA
Advisory Panel in October 2012.
Other Hologic Product Advances Highlighted This Year
Selenia and Selenia Dimensions 2D mammography systems continue
to be recognized as the standard-bearers for the industry, ranking
second and third, respectively, in the digital mammography category
in the KLAS 2012 annual survey of healthcare executives and
clinicians.
New this year is the Selenia Dimensions 2D Screening Package, an
elegant solution for customers seeking a cost-effective addition to
their breast cancer screening capabilities. The Dimensions 2D
Screening Package can be upgraded quickly and efficiently to
include diagnostic, interventional, or tomosynthesis capabilities,
giving facilities unlimited flexibility in expanding service
offerings at a time of their choosing.
Also on display this year is Hologic's Selenia Dimensions 2D
Contrast Imaging Option, an effective means of adding physiological
information to a diagnostic exam. This option is CE marked and
pending FDA clearance.
Hologic's Image Analytics innovations include Quantra breast
density assessment software, designed to provide a BI-RADS-like
value for the consistent reporting of breast composition and
Hologic's BACS (Breast Arterial Calcification Scoring) software
package. BACS can be used to evaluate calcified plaques in
arteries. Quantra is CE marked and cleared for sale in the U.S.
BACS is CE marked and pending FDA approval.
In the biopsy area Hologic is premiering a new introducer for
use with the ATEC biopsy system under ultrasound guidance. One
insertion allows for both biopsy needle placement and marker
deployment.
In breast MRI, Hologic is showing a new 16-channel Sentinelle
Breast Coil array designed to provide excellent signal-to-noise
ratio as well as optimal access for breast biopsies.
In Skeletal Health, Hologic is highlighting two products. The
first is a new Advanced Body Composition Assessment package on the
Discovery platform. This package is designed to assist
clinicians with the diagnosis and monitoring of obesity related
metabolic diseases, athletic training regimens and sports injury
rehabilitation programs. The second, shown for the first time at
RSNA as a commercial product, is Hologic's Fluoroscan InSight-FD
Mini C-arm with flat panel detector technology. The product is
designed specifically for orthopedic and extremity surgeons and
offers a thin profile and improved workspace access with enhanced
ease of positioning.
For a more extensive listing of products that Hologic will be
featuring at RSNA 2012, click here.
About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems, and
surgical products. The Company operates four core business units
focused on diagnostics, breast health, GYN surgical and skeletal
health. With a comprehensive suite of technologies and a robust
research and development program, Hologic is committed to improving
lives. The Company is headquartered in Massachusetts. For more information, visit
www.hologic.com.
Hologic, Advanced Body Composition, Affirm, ATEC, BACS, C-View,
Dimensions, Discovery, Fluoroscan, Quantra, Selenia and Sentinelle
are trademarks and/or registered trademarks of Hologic, Inc, and/or
its subsidiaries in the United
States and/or other countries.
BI-RADS is a registered trademark of the American College of
Radiology.
Forward Looking Statement Disclaimer
This News Release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic products. There can be no assurance the systems will
achieve the benefits described herein and that such benefits will
be replicated in any particular manner with respect to an
individual patient as the actual effect of the use of the systems
can only be determined on a case-by-case basis depending on the
particular circumstances and patient in question. Hologic expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to the data or statements presented herein to
reflect any change in the Company's expectations or any change in
events, conditions or circumstances on which any such data or
statements are based.
Contact:
|
|
Pat
Hall
Director
of Corporate Communications
pat.hall@hologic.com
781.999.7463 (Boston)
919.245.3460 (North Carolina)
919.622.1341 (mobile)
|
Jim
Culley
Sr. Director of Marketing
jim.culley@hologic.com
781.999.7583 (Boston)
302.528.1312 (mobile)
|
SOURCE Hologic, Inc.